TREATMENT METHODS FOR CONGENITAL DISORDERS OF GLYCOSYLATION (CDG) AND ATAXIA IN SUBJECTS SUFFERING FROM CDG
AR135367A1Pending Publication Date: 2026-09-02GLYCOMINE INC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- ARP20250100554
- Authority / Receiving Office
- AR · AR
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-02-29
- Filing Date
- 2025-02-28
- Publication Date
- 2026-09-02
Need to check novelty before this filing date? Find Prior Art
No text content released.
Claims
The disclosure provides phosphorylated carbohydrate replacement therapies (CRTs) that include phosphorylated carbohydrate compositions, such as mannose-1-phosphate (M1P), and phospholipids, as well as methods for preparing such compositions. These compositions are suitable for the pharmaceutical delivery of phosphorylated carbohydrates, such as M1P, for the treatment of CDG type I and CDG type II diseases, including congenital phosphomannomutase 2 glycosylation disorder (PMM2-CDG), as well as ataxia.